Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
En este video de discusión, el Dr. Narjust Duma habla con los Dres. Idalid "Ivy" Franco (Programa de Radiación Oncológica de Harvard), Ana Velázquez Manana (UCSF Helen Diller Family Comprehensive Cancer Center) y Luis Raez (Jefe de Hematología / Oncología y Director Médico - Memorial Cancer Institute) sobre cómo COVID 19 ha afectado la detección del cáncer en el comunidad latina, y la disminución en el diagnóstico de cáncer que se ha convertido en un problema en los Estados Unidos e internacionalmente.
*****
In this video discussion, Dr. Narjust Duma speaks with Drs. Idalid "Ivy" Franco (Harvard Radiation Oncology Program), Ana Velazquez Manana (UCSF Helen Diller Family Comprehensive Cancer Center) and Luis Raez (Chief Hematology/Oncology and Medical Director - Memorial Cancer Institute) about how COVID 19 has effected cancer screening in the latino community, and the decrease in cancer diagnosis that has become a problem in the US and internationally.
Para unirse a la conversación, visite https://cancergrace.org/forum.
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.